Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). It was developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd for the cure of non-small cell lung cancer (NSCLC). In May 2016, OTB was approved in South...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., Kadi, Adnan A., Darwish, Hany W., Abdelhameed, Ali S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091481/
https://www.ncbi.nlm.nih.gov/pubmed/35558213
http://dx.doi.org/10.1039/c8ra08161a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091481/
https://www.ncbi.nlm.nih.gov/pubmed/35558213
http://dx.doi.org/10.1039/c8ra08161a

Ejemplares similares